Colorectal Cancer (CRC) Clinical Trials in San Antonio, Texas
6 studies are recruiting for colorectal cancer (crc) in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- NEXT, San Antonio, Texas
- Locations
- 9 in total
- Run by
- Revolution Medicines, Inc.
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- NEXT Oncology, San Antonio, Texas
- Locations
- 10 in total
- Run by
- Cartography Biosciences
-
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- NEXT Oncology, San Antonio, Texas
- Locations
- 9 in total
- Run by
- Revolution Medicines, Inc.
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- START, San Antonio, Texas
- Locations
- 17 in total
- Run by
- Revolution Medicines, Inc.
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- NEXT Oncology, San Antonio, Texas
- Locations
- 8 in total
- Run by
- Bristol-Myers Squibb
-
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Next Oncology, San Antonio, Texas
- Locations
- 21 in total
- Run by
- Revolution Medicines, Inc.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.